Analytical capability of a medium power capacitively coupled plasma for the multielemental determination in multimineral/multivitamin preparations by atomic emission spectrometry

Simultaneous separation of arsenic and cadmium from interfering salt matrix of multivitamin/mineral supplements by sequential coprecipitation and determination by inductively coupled plasma mass spectrometry

Multivitamin/mineral (MVM) supplements possess highly saline matrix which, unless eliminated, precludes accurate determination of trace amounts of toxic metal impurities by inductively coupled plasma mass spectrometry (ICP-MS). Multi-step separations (up to four-steps) are described in literature; often for single element determinations due to difficulties in removing the matrix components. In this study, we developed a three-step sequential coprecipitation procedure for simultaneous separation of As and Cd impurities from MVM supplements for determination by ICP-MS. The procedure provided effective elimination of salt matrix, including Ca, Mg and KCl along with the interfering molybdenum (Mo) and tin (Sn) from MVM solutions. KCl, Mo and Sn were removed by two-step Mg(OH)₂ coprecipitation to about 34 µg mL^-1 K (ca. 31 µg mL^-1 Cl) and 0.4 µg mL^-1 Mo. Levels of Sn and Na were not significant. A third coprecipitation of the resulting MVM solution with HF + NH₄OH mixture precipitated virtually all Ca and Mg to as low as 1 and 10 µg mL^-1, respectively. The recoveries for As and Cd in the spiked MVM solutions were about 96% and 95%, respectively. The accuracy of the method was validated with analysis of multivitamin/multielement tablets certified reference material (SRM 3280). Experimental values were 112 ± 37 ng g^-1 for ⁷⁵As, and 76 ± 5, 79 ± 5, and 78 ± 7 ng g^-1 for ¹¹⁰Cd, ¹¹¹Cd and ¹¹⁴Cd isotopes, respectively, that were not significantly different from the certified values of As (132 ± 44 ng g^-1) and Cd (80.2 ± 0.9 ng g^-1) at 95% confidence level. Several commercially available MVM supplements were analyzed with the procedure. Mean As levels measured in the tablets varied between 24 and 128 ng g^-1 and that for Cd were between 28 and 125 ng g^-1 indicating total amount of As or Cd ingested per serving size were below the safe daily exposure limits. In addition, the results obtained for As and Cd with the procedure were lower in comparison to the values reported in literature indicating that ICP-MS analysis of complex MVM supplements could be prone to higher risks of inaccuracy without removal of interfering matrix.

A novel strategy for Cr(III) and Cr(VI) analysis in dietary supplements by speciated isotope dilution mass spectrometry

In recent years, Cr speciation in dietary supplements has become decisive in the evaluation of their health risks. Despite being an beneficial micronutrient, Cr(III) can be toxic at living organisms at high concentrations, while Cr(VI) is known to be highly toxic and carcinogenic. The main objective of this work was to optimize an analytical methodology for the extraction and accurate quantification of Cr(III) and Cr(VI) in dietary supplements. The extraction of Cr species was carried out with 50mM EDTA solution on a hotplate under optimized conditions. Special attention was paid to bidirectional species transformations. No noticeable oxidation of Cr(III) into Cr(VI) was observed and the reduction to Cr(III) only occurred at very high Cr(VI) concentrations. Cr(III) as Cr(EDTA)(-) complex was chromatographically separated from Cr(VI), retained as CrO4(2-), on an anion exchange column coupled to inductively coupled plasma mass spectrometry (LC-ICP-MS). The limit of quantification (0.08µgg(-1)) was below the limit established for Cr enriched yeasts by the European Union. Eleven dietary supplements were analyzed and Cr(III) and Cr(VI) quantification was carried out by external calibration monitoring (52)Cr isotope and by speciated isotope dilution mass spectrometry (SIDMS) adding (50)Cr(III) and (53)Cr(VI) spikes. Total Cr was also quantified by ICP-MS and mass balance between total Cr and the sum of Cr(III) and Cr(VI) was achieved. In eight of the eleven tested supplements Cr(III) calculated amounts were higher than those indicated by the manufacturer, but only one of them exceeded the 250µgday(-1) recommended by World Health Organization (WHO). In contrast, it is worth noting that Cr(VI) amounts beyond the recommendations of the European Union for Cr enriched yeasts were found in five supplements. These results revealed that more accurate and rigorous quality assurance protocols should be applied to the testing of the final products, including the analysis of both Cr(III) and Cr(VI).